Abzena : Blocklisting update

Abzena plc

Block Listing Update

Cambridge, UK, 9 January 2017- Further to the announcement by Abzena plc (AIM: ABZA, 'Abzena' or the 'Group')on 6 July 2016, the Group announces that a total of 75,000 ordinary shares of £0.002 each in the share capital of the Group ('Ordinary Shares') have been issued since that date pursuant to the Group's 2013 Share Incentive Plan and admitted to trading in accordance with the block listing applied for on 7 July 2015 (the 'Block Listing'). An update in accordance with Schedule 6 of the AIM Rules for Companies is set out below.

The Group holds no shares in treasury and hence the total number of current voting rights is 137,130,555.The Group will notify on a monthly basis when there are changes to the issued share capital, and these monthly figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Group.

BLOCK LISTING SIX MONTHLY RETURN

Name of applicant:		Abzena plc
Name of scheme:		Abzena plc 2013 Share Incentive Plan
Period of return:	From:	6 July 2016	To:	6 January 2017
Balance of unallotted securities under scheme(s) from previous return:		832,476
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil
Less: Number of securitiesissued/allotted under scheme(s) during period (see LR3.5.7G):		75,000
Equals: Balance under scheme(s) not yet issued/allotted at end of period		757,476
Number and class of securities originally admitted and the date of admission		1,779,000 ordinary shares of £0.002 each, admitted on 13 July 2015
Name of contact:		Julian Smith
Telephone number of contact:		[phone]

Enquiries:

Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer	[phone]
Numis (Nominated Adviser and Broker) Clare Terlouw / James Black / Paul Gillam	[phone]
N+1 Singer (Joint Broker) Aubrey Powell / Liz Yong	[phone]
Instinctif Partners Melanie Toyne Sewell / Rozi Morris	[phone] [e-mail]

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.

The term 'Abzena inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'Abzena inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).

· Immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.

· Contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.

· Proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.

· Contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture ADCs to GMP standards.

For more information, please see www.abzena.com